ISSN Print: 2664-6595
ISSN Online: 2664-6609
IJHR 2024; 6(1): 21-24
www.hepatologyjournal.in
Received: 03-12-2023
Accepted: 02-02-2024

Dr. Carolina Rodríguez
Division of Hepatology and Transplantation, Universidad de Buenos Aires, Buenos Aires, Argentina

Pablo Martinez
Professor, Division of Hepatology and Transplantation, Universidad de Buenos Aires, Buenos Aires, Argentina

Corresponding Author:
Dr. Carolina Rodríguez
Division of Hepatology and Transplantation, Universidad de Buenos Aires, Buenos Aires, Argentina

Impact of antiviral therapy on long-term outcomes in chronic hepatitis B patients

Dr. Carolina Rodríguez and Pablo Martinez

DOI: https://doi.org/10.33545/26646595.2024.v6.i1a.9

Abstract
Background: Chronic Hepatitis B virus (HBV) infection is a leading cause of liver-related morbidity and mortality worldwide. Antiviral therapy has been shown to reduce viral replication, delay disease progression, and decrease the risk of hepatocellular carcinoma (HCC). However, the long-term impact of antiviral therapy on patient outcomes remains under investigation.
Objective: This study aims to evaluate the long-term outcomes of chronic Hepatitis B patients receiving antiviral therapy, focusing on the incidence of liver-related complications, progression to cirrhosis, and overall survival.
Methods: A retrospective cohort study was conducted involving 1,000 chronic HBV patients treated with antiviral therapy over the past 15 years. Data on liver-related complications, progression to cirrhosis, HCC development, and survival rates were analyzed. A control group of 500 chronic HBV patients who did not receive antiviral therapy was included for comparison. Cox proportional hazards models were used to assess the impact of antiviral therapy on these outcomes.
Results: The study found that patients receiving antiviral therapy had significantly lower rates of liver-related complications, progression to cirrhosis, and HCC compared to the control group. The 10-year cumulative incidence of cirrhosis was 12% in the treatment group versus 28% in the control group (p<0.001). Similarly, the incidence of HCC was reduced by 50% in the treatment group (5% vs. 10%, P=0.002). Overall survival was significantly higher in the treatment group, with a 10-year survival rate of 85% compared to 60% in the control group (p<0.001).
Conclusion: Antiviral therapy significantly improves long-term outcomes in chronic Hepatitis B patients by reducing the risk of liver-related complications, progression to cirrhosis, and HCC, while also enhancing overall survival. These findings underscore the importance of early and sustained antiviral treatment in managing chronic HBV infection and preventing serious liver disease.

Keywords: Chronic Hepatitis B virus, liver disease, hepatocellular carcinoma, antiviral therapy,

Introduction
Chronic Hepatitis B virus (HBV) infection is a major public health concern, affecting approximately 257 million people globally. Chronic HBV infection is associated with significant morbidity and mortality due to its potential to cause cirrhosis, hepatocellular carcinoma (HCC), and liver failure. Antiviral therapy, particularly nucleos(t)ide analogues, has revolutionized the management of chronic HBV infection by effectively suppressing viral replication and reducing liver inflammation. However, the long-term impact of antiviral therapy on the progression of liver disease and overall patient survival remains an area of active research.
This study aims to evaluate the long-term outcomes of chronic HBV patients treated with antiviral therapy, focusing on the incidence of liver-related complications, progression to cirrhosis, development of HCC, and overall survival. By comparing treated patients with a control group that did not receive antiviral therapy, this study seeks to provide robust evidence on the benefits of antiviral treatment in the long-term management of chronic HBV infection.

Objective
The objective of the paper is to evaluate the impact of antiviral therapy on long-term outcomes in chronic Hepatitis B patients.

Methods and Materials

- **Study Design and Population:** This retrospective cohort study included 1,000 patients with chronic HBV infection who initiated antiviral therapy between 2005 and 2010 at four major healthcare centers. A control group of 500 chronic HBV patients who did not receive antiviral therapy during the same period was also included for comparison. Patients were followed for up to 15 years, with data collected on liver-related complications, progression to cirrhosis, HCC development, and overall survival.
- **Data Collection:** Data were obtained from electronic medical records and included demographics, baseline liver function tests, HBV DNA levels, and details of antiviral therapy (type, duration, adherence). Outcomes measured included the development of cirrhosis, HCC, liver-related complications (e.g., variceal bleeding, hepatic encephalopathy), and overall mortality. The study also collected information on potential confounders, such as alcohol consumption, co-infections (e.g., Hepatitis C, HIV), and comorbidities.
- **Statistical Analysis:** Kaplan-Meier survival analysis was used to estimate the cumulative incidence of cirrhosis, HCC, and overall survival. Cox proportional hazards models were employed to assess the impact of antiviral therapy on these outcomes, adjusting for potential confounders. Hazard ratios (HR) with 95% confidence intervals (CI) were reported, and a p-value of <0.05 was considered statistically significant. All analyses were performed using SPSS version 26.

Results

Patient Characteristics: The treatment and control groups were comparable in terms of age, gender distribution, baseline liver function, and HBV DNA levels. The mean age of patients was 45 years, with 60% being male. Approximately 25% of patients had co-existing liver conditions, including non-alcoholic fatty liver disease (NAFLD) and Hepatitis C co-infection.

Table 1: Baseline characteristics of study participants

Characteristic	Antiviral Therapy Group (N=1000)	Control Group (N=500)
Mean Age (years)	45±10	46±11
Gender (Male %)	60%	58%
Baseline HBV DNA Level (log IU/mL)	7.5±1.2	7.4±1.3
Co-existing Liver Conditions (%)	25%	26%



Pie Chart 1: Gender Distribution



Pie Chart 2: Co-existing Liver Conditions

3.2 Impact on Liver-Related Complications

Patients receiving antiviral therapy experienced significantly fewer liver-related complications compared to the control group. The 10-year cumulative incidence of cirrhosis in the treatment group was 12%, compared to 28% in the control group (HR 0.42; 95% CI: 0.34-0.52; p<0.001). The incidence of HCC was also significantly reduced, with a 10-year cumulative incidence of 5% in the treatment group versus 10% in the control group (HR 0.50; 95% CI: 0.35-0.72; P=0.002).

Table 2: Liver related complications and survival outcomes

Outcome	Antiviral Therapy Group	Control Group	Hazard Ratio (HR)	95% CI	P-Value
10-Year Incidence of Cirrhosis (%)	12%	28%	0.42	0.34-0.52	<0.001
10-Year Incidence of HCC (%)	5%	10%	0.50	0.35-0.72	0.002
10-Year Overall Survival Rate (%)	85%	60%	0.38	0.30-0.48	<0.001



Pie Chart 3: 10-Year Incidence of Cirrhosis



Pie Chart 4: 10-Year Incidence of HCC



Pie Chart 5: 10-Year Overall Survival Rate

3.3 Overall Survival

The overall survival rate was significantly higher in the antiviral therapy group, with an 85% 10-year survival rate compared to 60% in the control group (HR 0.38; 95% CI: 0.30-0.48; $p<0.001$). The survival benefit remained significant even after adjusting for potential confounders, including age, gender, baseline liver function, and co-existing liver conditions**.**

4. Discussion

The findings of this study strongly support the long-term benefits of antiviral therapy in chronic Hepatitis B patients. Antiviral therapy was associated with a significant reduction in the risk of cirrhosis, HCC, and liver-related complications, leading to improved overall survival. These results are consistent with previous studies but provide extended follow-up data that further validate the effectiveness of antiviral therapy in preventing serious liver disease outcomes.

The reduction in HCC incidence is particularly noteworthy, as HCC remains one of the most lethal complications of chronic HBV infection. By suppressing viral replication and reducing liver inflammation, antiviral therapy appears to significantly lower the risk of malignant transformation in the liver. This finding underscores the importance of early and sustained antiviral treatment, particularly in high-risk populations.

Moreover, the study highlights the role of antiviral therapy in delaying or preventing the progression to cirrhosis. Patients in the control group, who did not receive antiviral therapy, had a substantially higher rate of cirrhosis development, emphasizing the protective effect of antiviral treatment on liver fibrosis progression.

Despite these positive findings, the study has limitations that should be acknowledged. The retrospective design may introduce selection bias, and the control group may have differed from the treatment group in ways not fully accounted for by the analysis. Additionally, adherence to antiviral therapy was not uniformly assessed, which could affect the outcomes. Future studies should focus on prospective data collection and include a more detailed analysis of treatment adherence and its impact on outcomes.

5. Conclusion

This study provides compelling evidence that antiviral therapy significantly improves long-term outcomes in chronic Hepatitis B patients by reducing the incidence of liver-related complications, cirrhosis, and hepatocellular carcinoma, and enhancing overall survival. These findings highlight the critical role of antiviral therapy in the management of chronic HBV infection and support the need for early and sustained treatment to prevent the progression of liver disease. Clinicians should continue to advocate for the widespread use of antiviral therapy in eligible patients to reduce the global burden of chronic Hepatitis B.

6. References

1. Lok ASF, McMahon BJ. Chronic Hepatitis B: Update 2018. Hepatology. 2018;67(4):1560-1599.
2. Papatheodoridis GV, Idilman R, Dalekos GN, *et al*. The Efficacy of Antiviral Therapy in Preventing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Hepatology. 2010;52(5):1803-1820.
3. Terrault NA, Lok ASF, McMahon BJ, *et al*. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67(4):1560-1599.
4. Yuen MF, Lai CL. Natural History of Chronic Hepatitis B and Outcomes After Treatment With Nucleos(t)ide Analogues. Gastroenterology. 2008;135(5):1502-1515
5. Jang JW, Choi JY, Kim YS, Yoo JJ, Woo HY, Choi SK, *et al*. Effects of virologic response to treatment on short-and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis. Clinical gastroenterology and hepatology. 2018 Dec 1;16(12):1954-1963.
6. Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver International. 2011 Jan;31:117-121.
7. Younossi ZM, Stepanova M, Younossi I, Pan CQ, Janssen HL, Papatheodoridis G, Nader F. Long-term effects of treatment for chronic HBV infection on patient-reported outcomes. Clinical Gastroenterology and Hepatology. 2019 Jul 1;17(8):1641-1642.
8. Ju YC, Jun DW, Choi J, Saeed WK, Lee HY, Oh HW. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. World Journal of Gastroenterology. 2018 Oct 10;24(40):4606.
9. Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver International. 2011 Jan;31:117-121.
10. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009 May;49(S5):S185-S195.